Deborah is the Principle Scientist at Tessa Therapeutics where her work focuses on developing and qualifying molecular assays for characterization or lot release of Tessa's cell therapy products targeting a wide range of cancer indications. Before joining Tessa, Deborah worked at MSD, where she utilized her diverse experience in genetics and genomics to identify novel targets and to validate exploratory and clinical biomarkers across different therapeutic areas. Deborah holds a Ph.D. in Molecular Microbiology and Microbial Pathogenesis from Washington University in Saint Louis (USA).